Symphogen A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Subsidiary

Established: 2000-01-01

Employees: 101

Market Cap: -

Website: http://www.symphogen.com

Clinical Trials

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Phase 1

Completed

Conditions: Solid Tumor
Metastatic Cancer

Interventions: Drug: Sym024
Drug: Sym021

First Posted Date: 2020-12-17

Last Posted Date: 2024-12-09

Lead Sponsor: Symphogen A/S

Target Recruit Count: 48

Registration Number: NCT04672434

Locations: 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 1 locations

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Phase 1

Completed

Conditions: Metastatic Cancer
Solid Tumor

Interventions: Drug: Sym021
Drug: Sym023
Drug: Sym022
Drug: Irinotecan Hydrochloride

First Posted Date: 2020-11-24

Last Posted Date: 2024-06-26

Lead Sponsor: Symphogen A/S

Target Recruit Count: 78

Registration Number: NCT04641871

Locations: 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
University of Kansas Medical Center (KUMC), Westwood, Kansas, United States
🇺🇸
START Midwest, Grand Rapids, Michigan, United States

and more 14 locations

Sym004 Versus TAS-102 in Patients With mCRC

Phase 3

Withdrawn

Conditions: Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Carcinoma

Interventions: Drug: Sym004
Drug: TAS-102

First Posted Date: 2018-10-23

Last Posted Date: 2019-02-04

Lead Sponsor: Symphogen A/S

Registration Number: NCT03717038

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Phase 2

Terminated

Conditions: Colorectal Cancer Metastatic
Metastatic Colorectal Cancer
Carcinoma

Interventions: Drug: Sym004
Drug: Modotuximab
Drug: Futuximab

First Posted Date: 2018-06-08

Last Posted Date: 2020-09-28

Lead Sponsor: Symphogen A/S

Target Recruit Count: 2

Registration Number: NCT03549338

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇪🇸
Hospital Clínico de Valencia, Valencia, Spain
🇩🇪
Asklepios Kliniken Altona, Hamburg, Germany

and more 15 locations

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Phase 1

Completed

Conditions: Metastatic Cancer
Solid Tumor
Lymphoma

Interventions: Drug: Sym022

First Posted Date: 2018-04-05

Last Posted Date: 2021-02-18

Lead Sponsor: Symphogen A/S

Target Recruit Count: 15

Registration Number: NCT03489369

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Phase 1

Completed

Conditions: Metastatic Cancer
Lymphoma
Solid Tumor

Interventions: Drug: Sym023

First Posted Date: 2018-04-05

Last Posted Date: 2021-10-12

Lead Sponsor: Symphogen A/S

Target Recruit Count: 24

Registration Number: NCT03489343

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States

and more 1 locations

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Phase 1

Completed

Conditions: Solid Tumor
Metastatic Cancer
Lymphoma

Interventions: Drug: Sym021
Drug: Sym022
Drug: Sym023

First Posted Date: 2017-10-17

Last Posted Date: 2023-05-30

Lead Sponsor: Symphogen A/S

Target Recruit Count: 89

Registration Number: NCT03311412

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

and more 1 locations

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Phase 2

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Sym004

First Posted Date: 2016-11-16

Last Posted Date: 2017-02-01

Lead Sponsor: Symphogen A/S

Registration Number: NCT02965417

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Sym004
Drug: Nivolumab

First Posted Date: 2016-10-05

Last Posted Date: 2017-08-28

Lead Sponsor: Symphogen A/S

Registration Number: NCT02924233

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

Phase 1

Terminated

Conditions: Oncology

Interventions: Drug: Sym013

First Posted Date: 2016-09-20

Last Posted Date: 2020-08-28

Lead Sponsor: Symphogen A/S

Target Recruit Count: 32

Registration Number: NCT02906670

Locations: 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy